Synaptotagmin-like protein 2 gene promotes the metastatic potential in ovarian cancer

Sung,Hye Youn; Han,Jihye; Ju,Woong; Ahn,Jung-Hyuck

doi:10.3892/or.2016.4835

Synaptotagmin-like protein 2 gene promotes the metastatic potential in ovarian cancer

Authors:
- Hye Youn Sung
- Jihye Han
- Woong Ju
- Jung-Hyuck Ahn
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Ewha Womans University, Yangcheon-gu, Seoul 158-710, Republic of Korea, Department of Obstetrics and Gynecology, School of Medicine, Ewha Womans University, Yangcheon-gu, Seoul 158-710, Republic of Korea
Published online on: May 24, 2016 https://doi.org/10.3892/or.2016.4835
Pages: 535-541

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer (OC) metastasis has unique biological behavior and most commonly occurs via the transcoelomic route. Previously, we established a mouse xenograft model of human ovarian carcinoma and analyzed alterations in gene expression during metastasis. Among the genes that were differentially expressed more than 2-fold in the xenografts compared with the SK-OV-3 cells, we selected synaptotagmin-like protein 2 (SYTL2) and investigated the mechanisms regulating its expression and its gene function in OC. The mRNA expression of SYTL2 was significantly upregulated and the methylation of specific CpG sites within the SYTL2 promoter was decreased in the metastatic implants from the ovarian carcinoma xenografts compared to wild-type SK-OV-3 cells. Treatment with the demethylating agent 5-aza‑2'-deoxycytidine and/or the histone deacetylase inhibitor Trichostatin A induced upregulation of SYTL2 in SK-OV-3 cells, implying that a DNA methylation-dependent epigenetic mechanism is involved in the regulation of SYTL2 expression. We also found that overexpression of SYTL2 promoted metastatic potential, including increased migration and invasiveness in the ovarian carcinoma cells. Furthermore, we utilized publicly available gene expression data to confirm the correlation between SYTL2 expression and poor prognosis in serous-type OC patients. Our findings provide novel evidence for the direct association of SYTL2 with the metastatic potential of ovarian carcinoma cells and its influence on metastatic recurrence of OC.

View Figures

View References

1	Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH and Lee JS: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 46:109–123. 2014. View Article : Google Scholar : PubMed/NCBI
2	Yun JH, Lee HY, Park HW, Shin JW, Lee JM and Park CY: The analysis of prognostic factors in patients with epithelial ovarian cancer. Korean J Obstet Gynecol. 49:566–571. 2006.
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
4	Tummala MK and McGuire WP: Recurrent ovarian cancer. Clin Adv Hematol Oncol. 3:723–736. 2005.PubMed/NCBI
5	Feki A, Berardi P, Bellingan G, Major A, Krause KH, Petignat P, Zehra R, Pervaiz S and Irminger-Finger I: Dissemination of intraperitoneal ovarian cancer: discussion of mechanisms and demonstration of lymphatic spreading in ovarian cancer model. Crit Rev Oncol Hematol. 72:1–9. 2009. View Article : Google Scholar : PubMed/NCBI
6	Tan DS, Agarwal R and Kaye SB: Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 7:925–934. 2006. View Article : Google Scholar : PubMed/NCBI
7	Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, et al: Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b⁺ macrophages in advanced ovarian cancer. Cancer Res. 68:1100–1109. 2008. View Article : Google Scholar : PubMed/NCBI
8	Balch C, Fang F, Matei DE, Huang TH-M and Nephew KP: Minireview: epigenetic changes in ovarian cancer. Endocrinology. 150:4003–4011. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kim NH, Sung HY, Choi EN, Lyu D, Choi HJ, Ju W and Ahn JH: Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer. Oncol Rep. 31:2139–2146. 2014.PubMed/NCBI
10	Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:e32004.
11	Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 57:289–300. 1995.
12	Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, Wang XV, Ahmadifar M, Birrer MJ, Parmigiani G, et al: curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford). 2013:bat0132013. View Article : Google Scholar
13	Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI
14	Li L-C, Carroll PR and Dahiya R: Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 97:103–115. 2005. View Article : Google Scholar : PubMed/NCBI
15	Fukuda M: Rab27 and its effectors in secretory granule exocytosis: a novel docking machinery composed of a Rab27·effector complex. Biochem Soc Trans. 34:691–695. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kuroda TS, Fukuda M, Ariga H and Mikoshiba K: The Slp homology domain of synaptotagmin-like proteins 1-4 and Slac2 functions as a novel Rab27A binding domain. J Biol Chem. 277:9212–9218. 2002. View Article : Google Scholar : PubMed/NCBI
17	Fukuda M and Mikoshiba K: Synaptotagmin-like protein 1-3: a novel family of C-terminal-type tandem C2 proteins. Biochem Biophys Res Commun. 281:1226–1233. 2001. View Article : Google Scholar : PubMed/NCBI
18	Fukuda M, Saegusa C and Mikoshiba K: Novel splicing isoforms of synaptotagmin-like proteins 2 and 3: identification of the Slp homology domain. Biochem Biophys Res Commun. 283:513–519. 2001. View Article : Google Scholar : PubMed/NCBI
19	Torii S, Takeuchi T, Nagamatsu S and Izumi T: Rab27 effector granuphilin promotes the plasma membrane targeting of insulin granules via interaction with syntaxin 1a. J Biol Chem. 279:22532–22538. 2004. View Article : Google Scholar : PubMed/NCBI
20	Yu M, Kasai K, Nagashima K, Torii S, Yokota-Hashimoto H, Okamoto K, Takeuchi T, Gomi H and Izumi T: Exophilin4/Slp2-a targets glucagon granules to the plasma membrane through unique Ca²⁺-inhibitory phospholipid-binding activity of the C2A domain. Mol Biol Cell. 18:688–696. 2007. View Article : Google Scholar :
21	Kuroda TS and Fukuda M: Rab27A-binding protein Slp2-a is required for peripheral melanosome distribution and elongated cell shape in melanocytes. Nat Cell Biol. 6:1195–1203. 2004. View Article : Google Scholar : PubMed/NCBI
22	Yasuda T, Saegusa C, Kamakura S, Sumimoto H and Fukuda M: Rab27 effector Slp2-a transports the apical signaling molecule podocalyxin to the apical surface of MDCK II cells and regulates claudin-2 expression. Mol Biol Cell. 23:3229–3239. 2012. View Article : Google Scholar : PubMed/NCBI
23	Yasuda T and Fukuda M: Slp2-a controls renal epithelial cell size through regulation of Rap-ezrin signaling independently of Rab27. J Cell Sci. 127:557–570. 2014. View Article : Google Scholar
24	Ho JR, Chapeaublanc E, Kirkwood L, Nicolle R, Benhamou S, Lebret T, Allory Y, Southgate J, Radvanyi F and Goud B: Deregulation of Rab and Rab effector genes in bladder cancer. PLoS One. 7:e394692012. View Article : Google Scholar : PubMed/NCBI